Skip to main content

Site notifications

GARDASIL 9 Merck Sharp & Dohme (Australia) Pty Ltd

Product name
GARDASIL 9
Accepted date
May-2021
Active ingredients
HPV Type 45 L1 Protein, HPV Type 31 L1 Protein, HPV Type 33 L1 Protein, HPV Type 52 L1 Protein, HPV Type 11 L1 Protein, HPV Type 6 L1 Protein, HPV Type 58 L1 Protein, HPV Type 16 L1 Protein, HPV Type 18 L1 Protein
Proposed indication
To prevent infection against human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52 and 58.
Application type
C (new medicine)
Publication date
May-21

Registration process

Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.

Help us improve the Therapeutic Goods Administration site